Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 6, 2010, Pages 1445-1457

  Pendse, Gautam V ^a,b   Schwarz, Adam J ^b,c   Baumgartner, Richard ^b,d   Coimbra, Alexandre ^b,d   Upadhyay, Jaymin ^a,b   Borsook, David ^a,b,e   Becerra, Lino ^a,b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Imaging Consortium for Drug Development (ICD)   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bias; General linear model (GLM); Pharmacological MRI (PhMRI); Robust; Singular value decomposition (SVD); Variance

Indexed keywords

BUPRENORPHINE; PLACEBO; OXYGEN;

ACCURACY; ARTICLE; BRAIN REGION; CONTRAST; HUMAN; IN VIVO STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STATISTICAL MODEL; VOLUNTEER; ALGORITHM; BRAIN; BRAIN MAPPING; CHEMISTRY; COMPUTER SIMULATION; MALE; NORMAL DISTRIBUTION; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SIGNAL PROCESSING; TIME;

ALGORITHMS; BRAIN; BRAIN MAPPING; BUPRENORPHINE; COMPUTER SIMULATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NORMAL DISTRIBUTION; OXYGEN; REPRODUCIBILITY OF RESULTS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TIME FACTORS;

EID: 77952873834     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22180     Document Type: Article

References (44)

1. Chen YC, Galpern WR, Brownell AL, et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997;38:389-398.
2. Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000;21:314-318. (Pubitemid 30642922)
3. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997;19:591-611.
4. Stein EA, Pankiewicz J, Harsch HH, et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 1998;155:1009-1015. (Pubitemid 28357723)
5. Reese T, Bjelke B, Porszasz R, et al. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed 2000;13:43-49.
6. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in Rat. Neuroimage 2000;11:13-23.
7. Scanley BE, Kennan RP, Gore JC. Changes in rat cerebral blood volume due to modulation of the 5-HT(1A) receptor measured with susceptibility enhanced contrast MRI. Brain Res 2001;913:149-155.
8. Lowe AS, Williams SC, Symms MR, Stolerman IP, Shoaib M. Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage 2002;17:902-910. (Pubitemid 35317023)
9. Jenkins BG, Sanchez-Pernaute R, Brownell AL, Chen YC, Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J Neurosci 2004;24:9553-9560. (Pubitemid 39441509)
10. Schwarz A, Gozzi A, Reese T, et al. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 2004;54:1-10.
11. Luo F, Xi ZX, Wu G, Liu C, Gardner EL, Li SJ. Attenuation of brain response to heroin correlates with the reinstatement of heroin-seeking in rats by fMRI. Neuroimage 2004;22:1328-1335. (Pubitemid 38829222)
12. Chen YI, Choi JK, Jenkins BG. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse 2005;55:80-88.
13. Jones N, O'neill MJ, Tricklebank M, Libri V, Williams SC. Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2005;180:743-751.
14. Kufahl PR, Li Z, Risinger RC, et al. Neural responses to acute cocaine administration in the human brain detected by fMRI. Neuroimage 2005;28:904-914. (Pubitemid 41713625)
15. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg 2006;103:208-216, table. (Pubitemid 44036061)
16. Littlewood CL, Jones N, O'neill MJ, Mitchell SN, Tricklebank M, Williams SC. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006;186:64-81.
17. Littlewood CL, Cash D, Dixon AL, et al. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006;32:1733-1746. (Pubitemid 44332281)
18. Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naive rat. Neuropsychopharmacology 2006;31:1690-1703. (Pubitemid 44106700)
19. Easton N, Marshall F, Fone K, Marsden C. Atomoxetine produces changes in cortico-basal thalamic loop circuits: assessed by phMRI BOLD contrast. Neuropharmacology 2007;52:812-826. (Pubitemid 46237640)
20. Liu CH, Greve DN, Dai G, Marota JJ, Mandeville JB. Remifentanil administration reveals biphasic phMRI temporal responses in rat consistent with dynamic receptor regulation. Neuroimage 2007;34:1042-1053. (Pubitemid 46394481)
21. Kufahl P, Li Z, Risinger R, et al. Expectation modulates human brain responses to acute cocaine: a functional magnetic resonance imaging study. Biol Psychiatry 2008;63:222-230. (Pubitemid 350299317)
22. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008;65:154-164. (Pubitemid 351214314)
23. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008;33:1690-1703. (Pubitemid 351684709)
24. Chin CL, Pauly JR, Surber BW, et al. Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors. Synapse 2008;62:159-168.
25. Bruns A, Kunnecke B, Risterucci C, Moreau JL, von Kienlin M. Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med 2009;61:1451-1458.
26. Schwarz AJ, Whitcher B, Gozzi A, Reese T, Bifone A. Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. J Neurosci Methods 2007;159:346-360. (Pubitemid 44920262)
27. Whitcher B, Schwarz AJ, Barjat H, Smart SC, Grundy RI, James MF. Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. Neuroimage 2005;24:281-295. (Pubitemid 41359025)
28. Friston KJ, Fletcher P, Josephs O, Holmes A, Rugg MD, Turner R. Event-related fMRI: characterizing differential responses. Neuroimage 1998;7:30-40. (Pubitemid 28355037)
29. Calhoun VD, Stevens MC, Pearlson GD, Kiehl KA. fMRI analysis with the general linear model: removal of latency-induced amplitude bias by incorporation of hemodynamic derivative terms. Neuroimage 2004;22:252-257.
30. Hopfinger JB, Buchel C, Holmes AP, Friston KJ. A study of analysis parameters that influence the sensitivity of event-related fMRI analyses. Neuroimage 2000;11:326-333. (Pubitemid 30194711)
31. Woolrich MW, Behrens TE, Smith SM. Constrained linear basis sets for HRF modelling using Variational Bayes. NeuroImage 2004;21:1748-1761.
32. Golub GH, van Loan CF. Matrix Computations. 3rd edition. Baltimore: Johns Hopkins University Press; 1996. 728 p.
33. Pendse GV, Baumgartner R, Schwarz A, Coimbra A, Borsook D, Becerra L. A Statistical Framework for Optimal Design Matrix Generation with Application to fMRI. IEEE Transactions on Medical Imaging 2010; Digital Object Identifier: 10.1109/TMI.2010.2044512.
34. Bullingham RE, McQuay HJ, Moore A, Bennett MR. Buprenorphine kinetics. Clin Pharmacol Ther 1980;28:667-672.
35. Downing JW, Leary WP, White ES. Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine. Br J Anaesth 1977;49:251-255. (Pubitemid 8051409)
36. Escher M, Daali Y, Chabert J, Hopfgartner G, Dayer P, Desmeules J. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin Ther 2007;29:1620-1631. (Pubitemid 47494544)
37. Rubins DJ, Guenther I, Meng X, et al. PET measurement of buprenorphine mu-opioid receptor occupancy in rat brain using [C-11] carfentanil. In: Proceedings of the World Molecular Imaging Conference, Nice, France, 2008.
38. Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 2007;61:101-110. (Pubitemid 44855745)
39. Ruppert D, Wand MP, Carroll RJ. Semiparametric regression. Cambridge: Cambridge University Press; 2003. 416 p.
40. Friston KJ, Frith CD, Turner R, Frackowiak RS. Characterizing evoked hemodynamics with fMRI. Neuroimage 1995;2:157-165.
41. Josephs O, Turner R, Friston K. Event-related f MRI. Hum Brain Mapp 1997;5:243-248.
42. Schwarz AJ, Whitcher B, Reese T, Gozzi A, Bifone A. Group-level data-driven phMRI analysis. In: Proceedings of the 13th Annual Meeting of ISMRM, Miami, Florida, 2005. (abstract 694).
43. Lindquist MA, Wager TD. Validity and power in hemodynamic response modeling: a comparison study and a new approach. Hum Brain Mapp 2007;28:764-784.
44. Bloom AS, Hoffmann RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum Brain Mapp 1999;8:235-244.